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ABSTRACT 
Background. We determined whether pulmonary gas exchange indices during submaximal exercise 
are different in heart-failure (HF) patients with combined post- and pre-capillary pulmonary 
hypertension (PPC-PH) vs. HF patients with isolated post-capillary PH (IPC-PH) or no-PH. Methods 
& Results. Pulmonary hemodynamics and pulmonary gas exchange were assessed during rest and 
submaximal exercise in 39 HF patients undergoing right-heart catheterization. Post-hemodynamic 
evaluation, patients were classified as having no-PH (n=11), IPC-PH (n=12) or PPC-PH (n=16). At 
an equivalent oxygen consumption, end-tidal CO2 (PETCO2) and arterial oxygen saturation (SaO2) 
were greater in no-PH and IPC-PH vs. PPC-PH patients (36.1±3.2 vs. 31.7±4.5 vs. 26.2±4.7 mmHg 
and 97±2 vs. 96 ±3 vs. 91±1%, respectively). Conversely, dead-space ventilation (VD/VT) and the 
ventilatory equivalent for carbon dioxide (V̇E/V̇CO2 ratio) were lower in no-PH and IPC-PH vs. PPC-
PH patients (0.37±0.05 vs. 0.38±0.04 vs. 0.47±0.03 and 38±5 vs. 42±8 vs. 51±8, respectively). The 
exercise-induced change in VD/VT, V̇E/V̇CO2 ratio and PETCO2 correlated significantly with the 
change in mean pulmonary arterial pressure, diastolic pressure difference and transpulmonary 
pressure gradient in PPC-PH patients only. Conclusion. Noninvasive pulmonary gas exchange 
indices during submaximal exercise are different in HF patients with combined post-and pre-
capillary PH compared to patients with isolated post-capillary PH or no-PH.  
 
Key Words. Diastolic pressure difference; pre- and post-capillary pulmonary hypertension; right-
heart catheterization; submaximal exercise.   
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INTRODUCTION 
Pulmonary hypertension (PH) is a hallmark of chronic heart failure (HF) and is associated with 
pulmonary edema, dyspnea, exercise intolerance, poor prognosis and increased mortality in HF 
patients (1-4). In patients with left heart disease (LHD), PH first manifests as a “passive” increase in 
post-capillary pulmonary venous pressure with a concomitant elevation in pulmonary arterial 
pressure (PAP) secondary to the increase in left ventricular filling pressure consistent with a failing 
left ventricle (5). However, many LHD patients also develop a form of pulmonary vascular disease 
that is associated with vasoconstriction and/or fixed structural remodeling of the pulmonary arterial 
resistance vessels. Previously termed “reactive” or “out-of-proportion” PH, this combined post-
capillary and pre-capillary form of PH is characterized by an excessive increase in PAP relative to 
the increase in pulmonary wedge pressure (PWP), an increase in the diastolic pressure difference 
(DPD) (defined as diastolic PAP – mean PWP), and an increase in pulmonary vascular resistance 
(PVR) (6-8). Although the temporality and precise etiology of the development of PPC-PH are 
relatively unknown, the development of post-capillary PH with a pre-capillary component is, 
importantly, associated with a further increase in mortality rate in the HF population (9). 
 
Chronic HF is also associated with derangements in ventilatory and pulmonary gas exchange indices 
at rest and during submaximal and maximal exercise [e.g., low end-tidal CO2 (PETCO2), reduced 
ventilatory efficiency (increased V̇E/V̇CO2)] that are likely related to the development and severity of 
PH (10-14). Indeed, we have shown that V̇E/V̇CO2 and PETCO2 are both significantly related to 
invasively determined mPAP and PVR during submaximal exercise in HF patients (13). Moreover, 
administration of the vasodilator sildenafil causes a significant reduction in PAP and PVR with a 
concomitant decrease in V̇E/V̇CO2 slope during exercise (i.e. improved breathing efficiency) in HF 
(10). More recently, Guazzi et al. (15) reported that a V̇E/V̇CO2 slope ≥ 36 in response to exercise 
was an excellent predictor of the presence of left sided PH in HF patients. In addition, it has been 
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shown that the V̇E/V̇CO2 slope (> 41), the change in PETCO2 (<1.2 mmHg) and the severity of 
oscillatory ventilation during exercise are associated with “reactive” PH in HF patients (14). Taken 
together, the aforementioned data suggest that the deleterious alterations in ventilatory parameters 
and pulmonary gas exchange during exercise in patients with HF are related to the development and 
severity of PH. The aim of the present study was to further determine whether measures of 
pulmonary exchange during submaximal exercise differed in HF patients with combined post- and 
pre-capillary PH compared to HF patients with isolated post-capillary PH or no PH. As such, it was 
anticipated that the findings of the present study would 1) reinforce the concept that measures of 
pulmonary gas exchange during cardiopulmonary exercise testing (CPET) provide a suitable tool for 
noninvasive detection of PH, and 2) add to the most recent literature suggesting that measures of 
pulmonary gas exchange during CPET allow differentiation of HF patients with post- and pre-
capillary pulmonary hypertension from patients with isolated post-capillary pulmonary hypertension.  
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METHODS 
Participants and ethical approval  
Thirty-nine adult patients (32 male, 7 female) with a history of HF undergoing right heart 
catheterization volunteered to participate in the present study. The patients recruited for the study 
were required to meet the following criteria: 1) ≥1 y history of known HF, 2) an ejection fraction of 
≤40%, and 3) a BMI <36.  At the time of study, all patients were receiving standard, optimized 
pharmacotherapies for the management of HF. Post-hemodynamic evaluation, the patients were 
classified as either 1) HF without PH [mean PAP (mPAP)  < 25 mmHg], 2) HF with isolated post-
capillary PH [mPAP ≥ 25 mmHg, mean PWP (mPWP) > 15 mmHg, DPD < 7 mmHg), or 3) HF with 
combined post-capillary and pre-capillary PH (mPAP ≥ 25 mmHg, mPWP > 15 mmHg, DPD ≥ 7 
mmHg) (all pressures measured at rest) according to current guidelines (8). Each participant gave 
written informed consent after being provided a detailed description of the study requirements. The 
experimental procedures were approved by the Mayo Clinic Institutional Review Board and were 
performed in accordance with the ethical standards of the Declaration of Helsinki.  
 
Standard clinical tests 
Prior to catheterization, each patient completed a range of standard clinical tests, including 
pulmonary function, echocardiography, six-minute walk test and blood analysis. The standard 
clinical tests were performed during a single day at least 24 h but not more than 7 days prior to the 
right-heart catheterization procedure. This was consistent with the normal protocol followed for 
patients undergoing clinically indicated right-heart catheterization.  
 
Hemodynamic evaluation and cardiopulmonary exercise test 
Right-heart catheterization was conducted as described previously (16). Briefly, with subjects well 
rested and in the supine position, a 22-gauge indwelling catheter was placed in the radial artery and a 
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7-French Swan-Ganz balloon-tipped catheter was advanced through the right side of the heart to the 
pulmonary artery via the right internal jugular vein. Minimal sedation was given only to the 
participants who required it. Diastolic PAP (dPAP) as well as mPAP and mPWP were measured via 
the pulmonary catheter. DPD was calculated as dPAP minus mPWP and TPG was computed as 
mPAP minus mPWP. Arterial and mixed venous blood was drawn simultaneously from the radial 
and the pulmonary artery, respectively, for measurement of arterial and mixed venous O2 partial 
pressure (PaO2 and PvO2) and saturation (SaO2 and SvO2). Arterial and mixed venous oxygen 
content (CaO2 and CvO2) were then computed as CaO2 = (1.34 × Hgb × SaO2) + (PaO2 × 0.0031) and 
CvO2 = (1.34 × Hgb × SvO2) + (PvO2 × 0.0031). Cardiac output (Q̇) was subsequently determined 
via direct Fick as oxygen consumption divided by (CaO2-CvO2). Pulmonary vascular resistance 
(PVR) was calculated as TPG divided by Q̇. 
 
Once the radial and pulmonary arterial catheters were placed, each patient rested quietly for 5 
minutes before performing submaximal exercise on a stationary recumbent cycle ergometer (Stress 
EchoBed, Medical Positioning Inc., Kansas City, MO).  The exercise protocol commenced at a 
workload of 10 W, after which the workload was increased by 10 W every 3 minutes. A pedal 
cadence of 60 rpm was maintained by each patient until they had completed 2-3 exercise stages 
and/or reached a perceived exertion of 12-13 (“somewhat hard”) on the Borg 6-20 scale. The 
aforementioned measures of pulmonary vascular pressures and central hemodynamics were assessed 
simultaneously with ventilatory and pulmonary gas exchange indices (Ultima CPX, MGC 
Diagnostics, St. Paul, MN) at rest and throughout exercise in each patient. Cardiac rhythm and heart 
rate (HR) were also monitored continually during exercise. Arterial and mixed venous blood was 
sampled at rest, during the final 30 s of each exercise stage, and at end exercise for the determination 
of PaO2, PvO2, SaO2 and SvO2. Additionally, SaO2 was estimated at rest and throughout exercise 
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with the use of a pulse oximeter (Masimo Rad-9, Masimo Corporation, Irvine, CA) and finger-tip 
sensor.  
 
Data analysis 
Minute ventilation (V̇E), tidal volume (VT), breathing frequency (fR), oxygen consumption (V̇O2), 
carbon dioxide production (V̇CO2), respiratory exchange ratio (RER) and end-tidal CO2 (PETCO2) 
were obtained breath-by-breath and averaged over a 30 s period at rest and the last 30 s of each stage 
during exercise. Similarly, HR and SaO2 (via pulse oximetry) were assessed beat-by-beat and 
averaged over a 30 s period at rest and the last 30 s of each stage during exercise. From these data, 
derived variables including V̇E/V̇CO2 ratio, dead-space ventilation (VD/VT, where VD = [PaCO2-
PECO2]/PaCO2), and oxygen pulse (V̇O2/HR) were calculated at rest and during exercise and 
averaged as described above. 
 
Statistical analyses 
One way analysis of variance (ANOVA), with Bonferroni post-hoc correction, was performed to 
compare 1) subject demographics, 2) clinical data, and 3) measures of pulmonary hemodynamics and 
pulmonary gas exchange at rest and during exercise between the 3 patient groups (HF with no PH vs. 
HF with isolated post-capillary PH vs. HF with combined post- and pre-capillary PH). Pearson 
product-moment correlation coefficient (r) was computed to assess the relationships between the 
change in key gas exchange and the change in hemodynamic measures associated with submaximal 
exercise. The acceptable type I error was set at P < 0.05 and data are expressed as group means ± SD. 
Statistical analyses were performed using SPSS version 12.0 for Windows (SPSS, Chicago, IL).  
 
 
 
8 
 
RESULTS 
Patient demographics and clinical data  
Patient demographics, medications and clinical data including right-heart catheterization, pulmonary 
function, echocardiography, six-minute walk distance and hematologic measurements are shown in 
Tables 1 and 2. Of the 39 patients studied, 10 were NYHA class II, 28 NYHA class III, and one 
NYHA class IV. Post-catheterization, 11 patients were categorized as HF without PH (no-PH), 12 as 
HF with isolated post-capillary PH (IPC-PH), and 16 as HF with combined post- and pre-capillary 
PH (PPC-PH). While the IPC-PH patients were a little older than the no-PH and PPC-PH patients, 
the three patient groups were well matched for sex distribution, height, weight and left ventricular 
ejection fraction (Table 1). On average, V̇O2peak and six-minute walk distance were greater in the no-
PH patients compared to IPC-PH and PPC-PH patients (Tables 1 and 2). Similarly, pulmonary 
function was more impaired in the IPC-PH and PPC-PH patients relative to the no-PH patients, but 
only significantly so for forced vital capacity (Table 2).   
       
Resting and exercise pulmonary vascular pressures and hemodynamics 
Pulmonary vascular pressures measured at rest are shown in Table 2. To accurately compare data 
from HF patients with PPC-PH, IPC-PH and no-PH during submaximal exercise, we compared 
pulmonary vascular pressures at a matched Q̇ of ~4.5 L/min; this was the level of cardiac output 
reached by every patient during exercise. At this given Q̇, mPAP was greater in the PPC-PH versus 
the no-PH (54.7 ± 6.6 vs. 31.9 ± 6.3 mmHg, P = 0.014) and, to a lesser extent, the IPC-PH patients 
(54.7 ± 6.6 vs. 45.1 ±7.4 mmHg, P = 0.033). In addition, mPWP was greater in the PPC-PH patients 
compared to the no-PH patients (31.6 ± 6.7 vs. 21.9 ± 7.5 mmHg, P = 0.011); mPWP was not 
different in the PPC-PH versus IPC-PH patients at this level of exercise (31.6 ± 6.7 vs. 33.7 ± 5.3 
mmHg, P = 0.527). Exercise was associated with a modest increase in group mean DPD in the PPC-
PH and IPC-PH patients only, but was greater at the matched Q̇ in the PPC-PH compared to both the 
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IPC-PH and no-PH patients (11.1 ± 7.0 vs. 4.2 ± 3.7 vs. 2.7 ± 2.6 mmHg, P ≤ 0.029). Moreover, 
PVR was largely unchanged from rest to submaximal exercise in all patient groups but was greater at 
a matched Q̇ in the PPC-PH patients compared to the no-PH patients (6.0 ± 2.7 vs. 1.9 ± 1.3 WU, P = 
0.014). It should be noted that although group mean PVR did not change with exercise in any patient 
group, we did observe substantial inter-individual differences in PVR response with 6 of the 
11(55%), 5 of the 12 (42%) and 6 of the 16 (35%) no PH, IPC-PH and PPC-PH patients, 
respectively, showing a reduction in PVR with exercise. Together, these data show that pulmonary 
vascular pressures and resistance were greater in the PPC-PH versus the IPC-PH and no-PH patients 
at rest and in response to submaximal exercise.  
 
Resting and exercise pulmonary gas exchange 
At rest, V̇E was slightly but significantly greater in patients with PPC-PH versus patients with no-PH; 
all other key ventilatory and gas exchange indices were similar and not statistically different between 
the patient groups at rest (Table 3 and Figure 1). To accurately compare data between patient groups 
during submaximal exercise, we compared pulmonary vascular pressures at a matched V̇O2 of ~0.60 
L/min. During exercise at this matched V̇O2, PETCO2 was lower in patients with IPC-PH compared 
to patients with no-PH (31.7 ± 4.5 vs. 36.1 ± 3.2 mmHg, P = 0.021) (Figure 1); this was the only gas 
exchange variable that was different during exercise in these two patient groups. At the same level of 
exercise, V̇E and V̇E/V̇O2 were greater in patients with PPC-PH versus patients with no-PH (Table 4). 
Additionally, VD/VT, V̇E/V̇CO2 and the PaCO2-PETCO2 difference were higher whereas PETCO2 
and SaO2 were lower in patients with PPC-PH compared to patients with no-PH and patients with 
IPC-PH (Table 4 and Figure 1). In combination, these data indicated pulmonary gas exchange, 
particularly measures of VD/VT, V̇E/V̇CO2, PaCO2-PETCO2 difference, PETCO2 and SaO2, are 
substantially impaired in PPC-PH compared to IPC-PH and no-PH patients during submaximal 
exercise. 
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Relationship between exercise gas exchange and pulmonary vascular pressures during 
submaximal exercise  
To determine the effect of pulmonary vascular pressure and resistance on pulmonary gas exchange 
during exercise, we assessed the relationships between the exercise-associated changes in key 
pulmonary gas exchange (VD/VT, V̇E/V̇CO2 ratio, PETCO2, SaO2) and pulmonary hemodynamic 
variables (mPAP, mPWP, DPD, TPG,) (i.e. from rest to exercise at a matched V̇O2). There was no 
relationship between the change in any pulmonary gas exchange measure and the change in any 
measure of pulmonary vascular pressure associated with submaximal exercise in the IPC-PH patients 
(Table 5). Conversely, there was a positive correlation between mPAP and V̇E/V̇CO2 ratio (P = 
0.012), and a negative relationship between mPAP and PETCO2 (P = 0.009) in patients with PPC-PH 
(Table 5). In addition, there was a positive relationship between DPD and VD/VT (P = 0.025) and 
V̇E/V̇CO2 ratio (P = 0.046), and a negative relationship between DPD and PETCO2 (P = 0.0182) 
(Figure 2). Moreover, TPG was positively related to VD/VT (P = 0.008) and V̇E/V̇CO2 ratio (P = 
0.001), and negatively related to PETCO2 (P = 0.002) in the PPC-PH patients (Table 5).. These 
findings suggest that the exacerbation in exercise pulmonary gas exchange abnormalities in patients 
with PPC-PH are related to the excessive rise in pulmonary vascular pressures experienced by these 
patients. 
  
DISCUSSION 
Main findings 
The main findings of the present study were: 1) at a similar level of submaximal exercise (matched  
Q̇), mean pulmonary artery pressure (mPAP), the diastolic pressure difference (DPD) and the 
transpulmonary pressure gradient (TPG) were greater in HF patients with combined post- and pre-
capillary PH (PPC-PH) compared to HF patients with isolated post-capillary PH (IPC-PH) and HF 
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patients with normal pulmonary vascular pressures (no-PH), 2) at a matched level of V̇O2, VD/VT, 
V̇E/V̇CO2 and the PaCO2-PETCO2 difference were higher whereas PETCO2 and SaO2 were lower in 
patients with PPC-PH compared to patients with either IPC-PH or no-PH, and 3) the exercise 
associated change in VD/VT, V̇E/V̇CO2 ratio and PETCO2 correlated significantly with the change in 
mPAP, DPD and TPG in the PPC-PH patients only. Importantly, we believe that this is the first study 
to 1) report that the pulmonary gas exchange responses to submaximal exercise are different in HF 
patients with different forms of PH with HF patients stratified according to PH type based on the 
most recent World Symposium on PAH recommendations (8), and 2) demonstrate significant 
relationships between several indices of pulmonary gas exchange and pulmonary haemodynamics 
made simultaneously during exercise in HF patients with PPC-PH. These findings add to the recent 
and growing body of evidence which suggests that noninvasive measures of pulmonary gas exchange 
during submaximal exercise are different in HF patients with PPC-PH compared to patients with 
IPC-PH or no-PH, and that the exacerbation in pulmonary gas exchange abnormalities in patients 
with PPC-PH are related to the excessive rise in pulmonary vascular pressures and resistance 
experienced by these patients. 
 
Can exercise pulmonary gas exchange variables differentiate PH type and severity in HF? 
Patients with chronic HF commonly exhibit an excessive ventilatory response to exercise (12, 17) 
and experience significant derangements in pulmonary gas exchange at rest and during exercise (10-
13, 18). Previously, we have shown that the frequently observed increase in VD/VT and V̇E/V̇CO2 
during exercise in HF is due, at least in part, to a relative hyperventilation and a rapid and shallow 
breathing pattern (12), both of which are likely related to a reduction in lung compliance secondary 
to pulmonary congestion (19) and/or cardiomegaly (20). However, it is becoming increasingly clear 
that the progressive deterioration in pulmonary vascular function and the occurrence of PH in HF is 
not only associated with exercise intolerance (3, 21) but also further exacerbates pulmonary gas 
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exchange abnormalities in these patients. For example, we have shown that V̇E/V̇CO2 and PETCO2 
are both significantly related to invasively determined mPAP during submaximal exercise in HF 
patients, and that V̇E/V̇CO2 was greater and PETCO2 lower during exercise in HF patients with PH 
compared to HF patients without PH, although the difference in PETCO2 did not reach statistical 
significance (13). In addition, Guazzi et al. (15) reported that a V̇E/V̇CO2 slope ≥ 36 and, to a lesser 
extent, a peak PETCO2 ≤ 34 mmHg and the presence of oscillatory ventilation in response to exercise 
were excellent predictors of the presence of left sided PH in HF patients. Most recently, and perhaps 
most importantly, it has been shown that the V̇E/V̇CO2 slope (> 41) the change in PETCO2 (<1.2 
mmHg) and the severity of oscillatory ventilation during exercise are associated with “reactive” (or 
PPC-PH) PH in HF patients (14). In the present study, the main gas exchange abnormalities found in 
PPC-PH patients during submaximal exercise were an elevated VD/VT and V̇E/V̇CO2 and a lower 
PETCO2 and SaO2 compared to patients with IPC-PH or no-PH. Importantly, we also found that the 
exercise associated change in VD/VT, V̇E/V̇CO2 ratio and PETCO2 correlated significantly with the 
change in mPAP, DPD and TPG in the PPC-PH patients only; a finding novel to this study. In 
combination, the aforementioned findings suggest that the development of PH plays a role in the 
impaired pulmonary gas exchange commonly associated with HF, with the development of PPC-PH 
particularly associated with abnormal gas exchange during exercise in these patients. The 
mechanisms by which the elevated pulmonary vascular pressures associated with PPC-PH worsen 
exercise pulmonary gas exchange in these patients are multifactorial, but likely include the following.  
 
First, it is probable that the impaired pulmonary gas exchange observed in HF patients with PPC-PH 
is related to an inability to adequately increase pulmonary vascular perfusion during exercise 
secondary to the elevation in pulmonary vascular resistance and/or any fixed structural remodeling of 
the pulmonary arterial resistance vessels (6, 7). Indeed, the elevated PAP and PVR associated with 
PPC-PH likely restricts forward flow of blood from the right ventricle to the pulmonary vasculature, 
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while remodeling of the pulmonary resistance vessels would limit recruitment and distention of the 
pulmonary vasculature during exercise thus impairing expansion of the pulmonary vascular bed. 
Both of the aforementioned occurrences would cause an under-perfusion of ventilated alveoli and 
substantial ventilation-perfusion (V/Q̇) mismatching with an increase in the number of high V/Q̇ lung 
units. This V/Q̇ mismatching is likely a significant source of the elevated VD/VT and V̇E/V̇CO2, the 
reduced PETCO2 and the widening of the PaCO2-PETCO2 difference during submaximal exercise in 
HF patients with PPC-PH compared to patients with IPC-PH or no-PH observed in the present study 
(11, 18, 22-24).     
 
Second, an increase in pulmonary vascular pressures also impairs the cardiac output response to 
exercise with a resultant impairment in blood flow and subsequently O2 delivery to the working 
muscles (23). Any such reduction in O2 delivery to the working tissues likely induces early lactic 
acidosis during exercise with subsequent stimulation of ergoreceptors and/or chemoreceptors 
secondary to an elevation in CO2 and H
+ concentration and a consequent relative hyper-ventilatory 
response to exercise (23, 25). It is possible that such hyperventilation played a role in the increased 
VD/VT, the inefficient breathing (i.e. elevated V̇E/V̇CO2), and the reduced PETCO2 observed in 
patients with PPC-PH during submaximal exercise in present study. Indeed, in addition to the larger 
degree of impairment in key pulmonary gas exchange indices during submaximal exercise, we also 
found that PPC-PH patients exhibit an elevated V̇E response to exercise at an equivalent V̇O2 and 
work rate compared to patients with IPC-PH and no-PH. Thus, it is possible that a relative hyper-
ventilatory response to exercise caused by stimulation of ergoreceptors and/or chemoreceptors is a 
source of worsened pulmonary gas exchange in patients with PPC-PH.  
 
Finally, it is possible that an exercise-induced arterial hypoxemia increased ventilatory drive 
secondary to carotid body stimulation with a resultant exacerbation in the changes in VD/VT, 
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V̇E/V̇CO2 and PETCO2 in our PPC-PH patients. Despite the prevailing view that arterial oxygen 
levels are maintained at or above normal values in HF patients (26, 27), we have recently shown that 
HF patients with PPC-PH experience significant systemic hypoxemia relative to HF patients with 
IPC-PH or no-PH (16). In the present study, SaO2 was significantly reduced during submaximal 
exercise in the PPC-PH patients relative to the patients with IPC-PH or no-PH, with this reduction 
likely due to one or a combination of V/Q̇ mismatching, a reduction in the alveolar-capillary 
membrane for effective gas transfer, a reduction in cardiac output, and the possible occurrence of a 
right to left intra-atrial shunt(18, 22). While this hypoxemia may have contributed to the elevated V̇E 
and the abnormal exercise pulmonary gas exchange presently found in PPC-PH patients, it is likely 
that this effect was minimal owing to the fact that PPC-PH patients exhibited only a mild arterial 
hypoxemia (SaO2 during exercise ~91%) compared to the patients with IPC-PH or no-PH.  
 
Clinical relevance 
In current clinical practice, the presence and severity of PH in HF is determined via right-heart 
catheterization and disease status is tracked over time using a number of clinical and laboratory based 
measurements, including the six-minute walk test and echocardiography. While catheterization 
represents the gold standard for assessing pulmonary vascular pressures and function, it is highly 
invasive and the pressure signals are subject to interference from factors such as changes in lung 
volume and intrathoracic pressure swings. In addition, the 6-minute walk test is subject to a “plateau 
effect” that limits its sensitivity for detecting improvements in patients with greater walk distances, 
typically underestimates disease severity in younger patients, and ultimately provides limited 
physiological insight into the determinants of exercise intolerance (28, 29). Measurement of 
ventilatory and pulmonary gas exchange responses to exercise has a well-established role in the 
assessment of HF. Adding to the vast body of literature that has identified characteristic 
derangements in pulmonary gas exchange related to abnormal pulmonary hemodynamics, as well a 
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recent report which has shown that V̇E/V̇CO2 slope, the change in PETCO2 and the severity of 
oscillatory ventilation during exercise are associated with “reactive” PH in HF patients, the findings 
of the present study suggest that pulmonary gas exchange measures during clinical assessment may 
provide an efficacious adjunct to traditional clinical metrics for differentiation of PH type and 
severity in HF patients, and may help track disease status over time and assess the effectiveness of 
therapeutic aid.  
 
Conclusion  
Noninvasive measures of pulmonary gas exchange during submaximal exercise, specifically VD/VT, 
V̇E/V̇CO2, PETCO2 and SaO2, may help differentiate HF patients with combined post- and pre-
capillary PH from HF patients with isolated post-capillary PH or no PH, and may be a useful adjunct 
to invasive catheterization in assessing PH type and severity in patients with HF while providing a 
useful tool in tracking disease status, progression and response to therapy. 
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FIGURE LEGENDS 
Figure 1. Group mean ± SD mean dead-space ventilation (VD/VT) (A), ventilatory 
efficiency (V̇E/V̇CO2) (B), end-tidal carbon dioxide (PETCO2) (C), and arterial oxygen 
saturation (SaO2) (D) at rest and during submaximal exercise at a matched level of oxygen 
consumption (V̇O2) in heart failure patients (HF) with combined post-capillary and pre-
capillary pulmonary hypertension (PPC-PH) (open diamonds), HF patients with isolated 
post-capillary pulmonary hypertension (IPC-PH) (open circles), and HF patients with 
normal pulmonary vascular pressures (No-PH) (open squares). *P < 0.05, group mean value 
significantly different vs. No-PH group during exercise; †P < 0.05, group mean value 
significantly different vs. IPC-PH group during exercise. 
 
Figure 2. Scatter plots showing the relationships between the individual subject change in dead-
space ventilation (VD/VT; panel A), ventilatory equivalent for CO2 (V̇E/V̇CO2 ratio; panel B), partial 
pressure of end-tidal CO2 (PETCO2, panel C), and arterial oxygen saturation (SaO2) and the change 
in the diastolic pressure difference (DPD) associated with submaximal exercise in heart failure 
patients with combined post-capillary and pre-capillary pulmonary hypertension only.  
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Table 1. Patient demographics and medications 
 No-PH IPC-PH PPC-PH 
n, % female 11 (18) 12 (18) 16 (17) 
Age, y 52 ± 12 62 ± 6* 57 ± 9 
Height, cm 172 ± 8 172 ± 8 175 ± 8 
Weight, kg 83 ± 15 82 ± 14 90 ± 17 
VO2peak, ml/min 1012 ± 180 856 ± 168
* 835 ± 163* 
HF etiology          
   Ischemic 5 (45) 4 (36) 12 (71) 
   Idiopathic dilated 6 (55) 7 (66) 5 (29) 
HF duration, mo 48 ± 38 83 ± 97 63 ± 47 
LVEF, % 24 ± 8 25 ± 13 21 ± 9 
NYHA functional class          
   II 6 (55) 4 (33) 0 (0) 
   III 5 (45) 8 (67) 15 (94) 
   IV 0 (0) 0 (0) 1 (6) 
Medications          
   ACE inhibitor 11 (100) 6 (55) 9 (53) 
   β-blocker 10 (91) 8 (73) 14 (82) 
   Aspirin 8 (73) 6 (55) 12 (71) 
   Digitalis 7 (64) 5 (45) 12 (71) 
   Diuretic 8 (73) 10 (91) 16 (94) 
   Endothelinantagonist 0 (0) 0 (0) 0 (0) 
   PDE-5 inhibitor 0 (0) 1 (9) 0 (0) 
Data are presented as group mean ± SD or n (%). No-PH, normal pulmonary 
vascular pressures; IPC-PH, isolated post-capillary pulmonary hypertension; PPC-
PH, combined post-capillary and pre-capillary pulmonary hypertension; VO2peak, 
peak oxygen consumption; HF, heart failure; LVEF, left ventricular ejection 
fraction; NYHA, New York Heart Association; ACE, angiotensin converting 
enzyme; PDE, phosphodiesterase. 
*Value significantly different vs. No-PH group (P < 0.05). 
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Table 2. Resting pulmonary vascular pressures, pulmonary function and standard clinical 
measurements 
 
 No-PH IPC-PH PPC-PH 
RHC          
   mPAP, mmHg 17.3 ± 4.7 33.5 ± 5.6* 43.5 ± 6.8*† 
 (12 - 22) (26 - 40) (37 - 55) 
   mPWP, mmHg 9.1 ± 3.5 25.2 ± 5.2* 24.9 ± 7.3* 
 (3 - 14) (16 - 31) (13 - 37) 
   DPD, mmHg 2.95 ± 2.36 2.77 ± 2.00 8.46 ± 4.90*† 
 (−1 - 6) (−1 - 6) (7 - 24) 
   TPG, mmHg 8.2 ± 2.4 8.4 ± 2.5 18.6 ± 4.8*† 
 (4 - 11) (4 - 11) (13 - 29) 
   PVR, Wood units 2.0 ± 0.8 2.4 ± 1.0 5.8 ± 2.8*† 
 (1.2 - 2.8) (1.1 - 3.2) (2.8 - 11.4) 
Pulmonary function          
   FVC, % predicted 90 ± 10 68 ± 21* 74 ± 18* 
   FEV1, % predicted 83 ± 19 66 ± 21 68 ± 17 
   FEV1/FVC, % 73 ± 12 74 ± 7 72 ± 7 
Echocardiography          
   RAP, mmHg 3.8 ± 2.3 13.0 ± 4.7* 13.3 ± 6.7* 
   RVSP, mmHg 28.8 ± 7.2 47.1 ± 8.3* 64.5 ± 10.6*† 
Six-minute walk test          
   Distance, m 437 ± 139 360 ± 75 365 ± 70 
   Distance. % predicted 74 ± 26 70 ± 23 64 ± 14 
Blood work          
   Hemoglobin, g/dL 13.3 ± 1.4 12.4 ± 1.2 12.8 ± 1.9 
   BNP, pg/mL 195 ± 148 573 ± 462* 419 ± 389* 
   Endothlin-1, pg/mL 1.22 ± 0.50 2.26 ± 1.00 2.88 ± 1.78* 
   Angiotensin-II, pg/mL 13.02 ± 11.49 14.4 ± 10.8 16.8 ± 18.6 
   Epinephrine, pg/mL 79 ± 44 166 ± 132 86 ± 69 
   Norepinephrine, pg/mL 340 ± 187 549 ± 311 582 ± 256* 
Data are presented as group mean ± SD or group range (in parentheses). No-PH, normal 
pulmonary vascular pressures; IPC-PH, isolated post-capillary pulmonary hypertension; 
PPC-PH, combined post-capillary and pre-capillary pulmonary hypertension; RHC, right-
heart catheterization; mPAP, mean pulmonary arterial pressure; mPWP, mean pulmonary 
wedge pressure; DPD, diastolic PAP – mean PWP; TPG, transpulmonary pressure gradient; 
PVR, pulmonary vascular resistance; FVC, forced vital capacity; FEV1, forced expiratory 
volume in 1 s; RAP, right atrial pressure; RVSP, right ventricular systolic pressure; BNP, 
brain natriuretic peptide. 
*Value significantly different vs. No-PH group (P < 0.05); †Value significantly different vs. 
IPC-PH group (P < 0.05). 
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Table 3. Resting gas exchange, breathing pattern and hemodynamic variables 
 
 No-PH IPC-PH PPC-PH 
VO2, L/min 0.23 ± 0.06 0.23 ± 0.06 0.27 ± 0.08 
VCO2, L/min 0.19 ± 0.05 0.19 ± 0.06 0.24 ± 0.07 
RER 0.84 ± 0.07 0.84 ± 0.11 0.91 ± 0.11 
VE, L/min 8.1 ± 1.7 9.0 ± 3.4 11.1 ± 2.1
* 
VT, L 0.52 ± 0.24 0.50 ± 0.24 0.68 ± 0.28 
fR, breaths/min 17 ± 4 19 ± 7 18 ± 6 
VE/VO2 ratio 46 ± 8 50 ± 16 49 ± 9 
Q, L/min 4.6 ± 2.3 3.8 ± 1.5 3.8 ± 1.5 
SV, mL 72 ± 35 53 ± 22* 52 ± 21* 
HR, beats/min 64 ± 8 74 ± 11 75 ± 12 
PaCO2-PETCO2, mmHg 3.53 ± 2.42 4.11 ± 4.66 5.81 ± 2.87*† 
O2pulse, mL/beat 3.6 ± 1.0 3.1 ± 0.8 3.6 ± 1.1 
Data are presented as group mean ± SD. No-PH, normal pulmonary vascular pressures; 
IPC-PH, isolated post-capillary pulmonary hypertension; PPC-PH, combined post-capillary 
and pre-capillary pulmonary hypertension; VO2, oxygen consumption; VCO2, carbon 
dioxide production; RER, respiratory exchange ratio; VE, minute ventilation; VT, tidal 
volume; fR, respiratory frequency; Q, cardiac output; SV, stroke volume; HR, heart rate; 
PaCO2, partial pressure of arterial carbon dioxide; PETCO2, partial pressure of end-tidal 
carbon dioxide; O2pulse, oxygen pulse; OUES, oxygen uptake efficiency slope;  
*Value significantly different vs. No-PH group (P < 0.05); †Value significantly different vs. 
IPC-PH group (P < 0.05). 
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Table 4. Exercise responses at a matched oxygen consumption 
 
 No-PH IPC-PH PPC-PH 
Work rate, W 20 ± 0 28 ± 12* 22 ± 6 
VO2, L/min 0.59 ± 0.08 0.60 ± 0.07 0.60 ± 0.10 
VCO2, L/min 0.45 ± 0.08 0.54 ± 0.12 0.55 ± 0.13 
RER 0.92 ± 0.13 0.90 ± 0.11 0.93 ± 0.12 
VE, L/min 18.1 ± 3.9 23.5 ± 7.8 26.1 ± 7.5
* 
VT, L 0.78 ± 0.26 0.82 ± 0.31 0.94 ± 0.30 
fR, breaths/min 25 ± 8 27 ± 8 29 ± 6 
VE/VO2 ratio 35 ± 9 45 ± 12 50 ± 16
* 
Q, L/min 5.1 ± 1.1 4.6 ± 1.7 4.3 ± 1.4* 
SV, mL 55 ± 15 44 ± 17 46 ± 20 
HR, beats/min 95 ± 9 102 ± 16 106 ± 18 
PaCO2-PETCO2, mmHg 2.24 ± 1.78 4.07 ± 2.74 6.06 ± 2.06*† 
O2pulse, mL/beat 5.7 ± 1.0 5.3 ± 1.5 5.2 ± 1.4 
Data are presented as group mean ± SD. No-PH, normal pulmonary vascular pressures; 
IPC-PH, isolated post-capillary pulmonary hypertension; PPC-PH, combined post-capillary 
and pre-capillary pulmonary hypertension; VO2, oxygen consumption; VCO2, carbon 
dioxide production; RER, respiratory exchange ratio; VE, minute ventilation; VT, tidal 
volume; fR, respiratory frequency; Q, cardiac output; SV, stroke volume; HR, heart rate; 
PaCO2, partial pressure of arterial carbon dioxide; PETCO2, partial pressure of end-tidal 
carbon dioxide; O2pulse, oxygen pulse; OUES, oxygen uptake efficiency slope;  
*Value significantly different vs. No-PH group (P < 0.05); †Value significantly different vs. 
IPC-PH group (P < 0.05). 
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Table 5. Relationships between the change in key pulmonary gas exchange 
measures and the change in hemodynamic measures associated with submaximal 
exercise [(i.e. from rest to exercise at a matched oxygen consumption (VO2 ~0.60 
L/min)] 
 
 Isolated Post-capillary Pulmonary Hypertension 
 VD/VT VE/VCO2 
 
PETCO2 
(mmHg) 
SaO2 
(%) 
mPAP, mmHg 0.058 0.345 0.208 0.504 
mPWP, mmHg 0.179 0.602‡ 0.089 0.128 
DPD, mmHg 0.087 −0.113 0.152 0.288 
TPG, mmHg −0.191 −0.486 0.093 0.348 
  
Combined Post- and Pre-capillary Pulmonary Hypertension 
 VD/VT VE/VCO2 
 
PETCO2 
(mmHg) 
SaO2 
(%) 
mPAP, mmHg 0.377 0.528* −0.649† 0.090 
mPWP, mmHg -0.217 -0.119 −0.051 0.104 
DPD, mmHg 0.616* 0.599* −0.485* 0.034 
TPG, mmHg 0.618† 0.710† −0.706† 0.017 
Data are presented as Pearson-product moment correlation coefficients (r-values). 
mPAP, mean pulmonary arterial pressure; mPWP, mean pulmonary wedge pressure; 
DPD, diastolic pressure difference; TPG, transpulmonary pressure gradient.  
*Significant relationship between two variables (P < 0.05); †Significant relationship 
between two variables (P < 0.01); ‡Trend suggesting a significant relationship 
between two variables (P < 0.09). 
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Figure 1. 
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Figure 2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
